sumanirole
Sign in to saveSumanirole (PNU-95,666) is a highly selective D2 receptor full agonist, the first of its kind to be discovered. It was developed for the treatment of Parkinson's disease and restless leg syndrome. While it has never been approved for medical use it is a highly valuable tool compound for basic research to identify neurobiological mechanisms that are based on a dopamine D2-linked (vs. D1-, D3-, D4-, and D5-linked) mechanism of action.
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 203.105862
Show 4 more facts
- chemical formula
- C₁₁H₁₃N₃O
- isomeric SMILES
- CN[C@@H]1CC2=C3C(=CC=C2)NC(=O)N3C1
- canonical SMILES
- CNC1CC2=C3C(=CC=C2)NC(=O)N3C1
- Commons category
- Sumanirole
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Sumanirole (PNU-95,666) is a highly selective D2 receptor full agonist, the first of its kind to be discovered. It was developed for the treatment of Parkinson's disease and restless leg syndrome. While it has never been approved for medical use it is a highly valuable tool compound for basic research to identify neurobiological mechanisms that are based on a dopamine D2-linked (vs. D1-, D3-, D4-, and D5-linked) mechanism of action.
In 2004, Pfizer announced the end of their clinical development program for sumanirole, citing “recent studies that failed to sufficiently distinguish sumanirole from currently available therapies”.
Excerpted from Wikipedia’s “sumanirole” article, available under the CC BY-SA 4.0 licence.